The insider sales are too small to be informative. Focus on the upcoming PDUFA catalysts: Afrezza pediatric decision on May 29 (potential new patient population) and Furoscix ReadyFlow Autoinjector on July 26 (first IV-equivalent diuretic autoinjector). Q1 revenue growth of 15% and $134M cash position provide runway. Monitor for any insider buying ahead of these catalysts.
Price Chart
Executive Summary
Two insiders at MannKind Corp made open-market sales totaling $66K (0.007% of market cap) on May 12, 2026, one week after the company reported Q1 2026 revenue of $90.2M (+15% YoY) and highlighted upcoming PDUFA dates for Afrezza pediatric (May 29) and Furoscix ReadyFlow Autoinjector (July 26). The sales are trivial relative to the $1.0B market cap and are dwarfed by the $215K in tax-withholding share surrenders by the CEO and other executives on May 11, indicating the open-market sales are likely liquidity-driven rather than signaling a bearish view.
Key Financial Metrics
Key Facts
- Open-market sales: EVP Thomson sold $10K, Director Binder sold $56K — total $66K, or 0.007% of $1.0B market cap
- Tax-withholding share surrenders on May 11: CEO Castagna ($123K), EVP Thomson ($44K), Director Binder ($20K), CPWO Tross ($28K) — total $215K, non-cash events
- Q1 2026 revenue $90.2M (+15% YoY); Afrezza $15.3M (+3%), Furoscix $15.5M (new), royalties $32.7M (+9%)
- Two upcoming PDUFA dates: Afrezza pediatric (May 29, 2026) and Furoscix ReadyFlow Autoinjector (July 26, 2026)
- Cash and investments $134M as of March 31, 2026; $36.3M convertible notes settled for $35.5M cash + 569K shares
Financial Impact
Open-market sales of $66K represent 0.007% of market cap — immaterial
Risk Factors
- Afrezza pediatric PDUFA denial on May 29 would remove a key growth catalyst
- Furoscix ReadyFlow Autoinjector PDUFA denial on July 26 would slow Furoscix growth trajectory
- Selling, general and administrative expenses rose 116% YoY to $54.1M, pressuring margins
- R&D expenses rose 56% to $17.2M, reflecting pipeline investment but near-term cash burn
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-MNKD-1778718640742 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 29, 2026 9w ago | Press Release | $3.85 $4.09 | ▲ +6.23% | ▲ +1.21% | $3.74 (−2.86%) |
Jul 24, 2026 9w ago | 8-K | $3.95 $4.07 | ▲ +3.04% | ▼ −0.26% | $3.74 (−5.32%) |
Jul 18, 2026 10w ago | Insider Cluster | $3.98 $3.90 | ▼ −2.01% | ▼ −6.13% | $3.74 (−6.03%) |
Jun 3, 2026 17w ago | Press Release | $3.36 $4.52 | ▲ +34.52% | ▲ +35.52% | $3.74 (+11.31%) |
Jun 2, 2026 17w ago | 8-K | $3.43 $4.05 | ▲ +18.08% | ▲ +19.64% | $3.74 (+9.04%) |
May 29, 2026 18w ago | Press Release | $3.77 $4.24 | ▲ +12.47% | ▲ +14.26% | $3.74 (−0.80%) |
May 29, 2026 18w ago | Press Release | $3.77 $4.24 | ▲ +12.47% | ▲ +14.26% | $3.74 (−0.80%) |
May 28, 2026 18w ago | 8-K | $3.64 $4.14 | ▲ +13.74% | ▲ +16.88% | $3.74 (+2.75%) |
May 27, 2026 18w ago | Press Release | $3.55 $3.93 | ▲ +10.70% | ▲ +12.61% | $3.74 (+5.35%) |
May 12, 2026 20w ago | Insider Cluster | $3.28 $3.63 | ▲ +10.67% | ▲ +12.40% | $3.74 (+14.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access